Objective: Reduced serum adiponectin levels have been found in obesity and type 2 diabetes and variations in the adiponectin gene (APM1) have been associated with type 2 diabetes and features of the metabolic syndrome in different populations. Study Design: Here, we investigated the expression of APM1 in adipose tissue and studied the relationship between variation in APM1 expression, the APM1 G276T polymorphism, the common PPARG Pro12Ala polymorphism and clinical features of 36 morbidly obese (body mass index (BMI) 41.574.9 kg/m 2 ) nondiabetic subjects. Results: APM1 mRNA expression in visceral fat was correlated with serum adiponectin levels (r ¼ 0.54, P ¼ 0.012). In visceral, but not in subcutaneous, adipose tissue APM1 mRNA level was 38% higher among carriers of the APM1 G276T T allele
Introduction
The adipose tissue is a metabolically active tissue that produces and secretes a variety of proteins, such as tumor necrosis factor alpha, resistin, plasminogen activator inhibitor type 1, angiotensinogen, leptin and adiponectin, all of which have been ascribed a role in the pathogenesis of insulin resistance and obesity. [1] [2] [3] [4] [5] Plasma adiponectin levels are reduced in obesity, type 2 diabetes and cardiovascular disease and low adiponectin concentration is an independent risk factor for progression to type 2 diabetes. [5] [6] [7] [8] In analogy, high adiponectin plasma levels are associated with enhanced insulin sensitivity in nondiabetic subjects. 9 Variations in the adiponectin gene (APM1) have been associated with type 2 diabetes in many populations. [10] [11] [12] [13] [14] [15] [16] The adiponectin gene has thus emerged as a susceptibility gene for type 2 diabetes, as well as for cardiovascular disease and obesity. The intronic G276T variant, located in intron 2, is one of the most extensively studied variants within the adiponectin gene and has the most consistent published results. It has been associated with type 2 diabetes, insulin resistance, coronary artery disease and adiponectin level in several populations. 10, 14, [17] [18] [19] [20] The majority of these studies report the APM1 G276T G-allele as risk allele, with two exceptions. 14, 19 Earlier studies have shown that APM1 expression is reduced in visceral compared to subcutaneous adipose tissue in normal-weight subjects. 21 However, adiponectin secretion was higher in cultured human omental adipocytes than in subcutaneous adipocytes. 22 Adiponectin serum levels have a heritability of about 30%, 18 indicating that genetic variation within or outside the adiponectin gene could affect the expression of the gene. Several studies have reported an effect on serum adiponectin levels for different single nucleotide polymorphisms (SNPs) in the APM1 gene, 10, 12, [17] [18] [19] 23 but to our knowledge only one study has focused on the effect of a genetic marker on the APM1 mRNA expression in omental adipose tissue, reporting increased mRNA levels for the APM1 T94G G-allele. 24 Visceral adipose tissue is more metabolically active than subcutanoeus adipose tissue and is of greater importance for the development of obesity-related complications. 25 Therefore it is important to investigate both these adipose depots to detect differences in expression patterns and effects of genetic variants. The adiponectin gene is also regulated by the peroxisome proliferator-activated receptor gamma (PPARg) gene (PPARG). PPARg agonists increase adiponectin mRNA expression and secretion in cultured 3T3-L1 adipocytes, in db/db mice and the adiponectin concentrations in humans. 26 The aim of this study was to examine tissue-specific adiponectin mRNA expression in morbidly obese nondiabetic patients and whether this expression is influenced by the APM1 G276T or the PPARG Pro12Ala polymorphisms.
Methods

Study subjects
The study material has been described previously. 27 Visceral and subcutaneous adipose tissue was obtained peroperatively from 36 obese subjects, 32 females and 4 males, (body mass index (BMI) 41.574.9 kg/m 2 , age 37.2710.1 years) undergoing bariatric surgery at Landskrona hospital, Sweden. All subjects were Swedish, Caucasian and nondiabetic. Biopsies were frozen in liquid nitrogen and stored in À801 until used for analysis. The homeostasis model assessment (HOMA) was used for assessment of insulin resistance (insulin resistance index ¼ (fasting glucose (mmol/l) Â fasting insulin (U/ml))/ 22.5). 28 DNA could not be obtained from five of the patients.
Clinical characteristics for the subjects are shown in Table 1 . The study was approved by local ethics committee and all subjects gave informed consent.
Genotyping
The SNP located at position 276 (G4T) in intron 2 of APM1 and the PPARG Pro12Ala polymorphism were genotyped using allelic discrimination on the ABI PRISM 
Laboratory tests
Assessment of phenotypic characteristics has been described previously. 27 Briefly, blood was drawn from an antecubical vein after a 12-h overnight fast and plasma glucose was determined using an automated glucose oxidase method (Glucose Analyzer 2; Beckman Instruments, Fullerton, CA, USA). Serum insulin was determined using a radioimmuno assay (RIA) (Pharmacia, Uppsala, Sweden). Serum adiponectin and leptin levels were measured with human adiponectin and leptin RIA kits (Linco Research Inc, St Charles, MO, USA). BMI was calculated as weight (kg) divided by height (m) squared. Triglyceride levels were measured on a Cobas Mira analyzer (Hoffman-La Roche, Basel, Switzerland). Total body fat percentage was calculated using bioimpedance analysis.
Gene expression
Extraction of total RNA from the fat biopsies was performed with the RNeasy Mini kit (Qiagen, Germany) and cDNA synthesized using Superscript II RNase H -Reverse Transcriptase (Life Technologies, MD, USA) and random hexamer primers (Life Technologies, MD, USA). APM1 mRNA levels were quantified using real-time PCR on the ABI PRISM 7900 Sequence Detection System (Applied Biosystems) with forward primer:
and Cyclophilin A as endogenous control. All samples were run in duplicate and data were calculated using the standard curve method and expressed as a ratio to the Cyclophilin A reference (arbitrary units).
Statistical analysis
Descriptive data are presented as means7s.d. and expression data are presented as means7s.e.m. Differences were considered significant when P was less than 0.05. Statistical calculations were performed using the Number Cruncher [26] 115.2711.1 Fat % [31] 60.079.1 HOMA index [23] 4.074.2 Fasting glucose (mmol/l) [32] 4.970.6 Fasting insulin (mU/l) [24] 19.5716.8 Leptin (mg/l)
Males [3] 19.373.9 Females [25] 35.8710.7 Triglycerides (mmol/l) [27] 1.971.4 Adiponectin (mg/ml) [21] 14.476.9
Adiponectin gene expression J Fredriksson et al Statistical Software 2000 (NCSS, Kaysville, UT, USA). The significance of difference in mean values was tested by nonparametric statistics using P-values derived by Kruskal Wallis or Mann-Whitney, and the significance of relationship between variables was tested using Spearman's correlation coefficient. Wilcoxon signed-rank test was used to compare differences between paired variables. The w 2 test was used to detect deviations from the Hardy-Weinberg equilibrium. To obtain as much power as possible, the four male subjects were included in analysis; however, significant differences were reanalyzed in female subjects only. Owing to few subjects carrying the APM1 G276 T T/T and the PPARG Pro12Ala Ala/Ala genotypes, the APM1 G276 T T/T genotype was combined with the G/T genotype and the PPARG Pro12 Ala/Ala genotype was combined with the Pro/Ala genotype for most analyses.
Results
We investigated APM1 expression in subcutaneous and visceral adipose tissue and tested whether APM1 expression was influenced by variation in the gene in morbidly obese subjects. Clinical characteristics of the study subjects are found in Table 1 Allele frequencies for the APM1 G276T variant were 0.73 (G) and 0.27 (T). All genotype frequencies were in HardyWeinberg equilibrium. Carriers of the APM1 G276T T allele had significantly higher body fat percent (6576 vs 56710, P ¼ 0.011) compared to homozygous carriers of the G-allele (Table 3) . This difference remained also after excluding male subjects (6676 vs 57710, P ¼ 0.021 in female subjects only).
In an analysis including all three genotype groups, there was a significant difference in visceral but not in subcutaneous APM1 mRNA expression, with higher expression in carriers of the T allele (P ¼ 0.014) than in G/G genotype carriers (Figure 2 ) (in female subjects only: P ¼ 0.024). Visceral fat APM1 mRNA levels were 38% higher among carriers of the APM1 G276T T allele compared to G/G genotype carriers We were also interested in whether the PPARG Pro12Ala polymorphism would have an effect on the mRNA expression of APM1. Allele frequencies of the PPARG Pro12Ala variant were 0.81 (Pro) and 0.19 (Ala), and genotype frequencies were in Hardy-Weinberg equilibrium. We did not observe any difference in APM1 mRNA expression between the different PPARG genotype carriers (Table 4) . Neither was there any effect of combination of risk genotypes in both genes on mRNA expression (Table 4) .
Discussion
The key finding of the present study was that adiponectin mRNA concentrations in visceral fat correlated with serum adiponectin concentrations and that visceral APM1 mRNA expression levels are influenced by an intronic polymorphism in the gene. The absence of a difference between visceral and subcutaneous adiponectin mRNA levels in obese subjects is in line with a previous study which showed significantly lower APM1 mRNA levels in visceral compared to subcutaneous adipose tissue in lean subjects, but only a nonsignificant trend in obese subjects. 21 In humans, subcutaneous adiponectin mRNA levels are reduced in obesity, 29 independently of the degree of insulin resistance. 30 In obese type 2 diabetic subjects, both visceral and subcutaneous APM1 mRNA levels have been reported to be reduced. 31 Taken together, results suggest that there is no difference in APM1 mRNA expression between subcutaneous and visceral adipose tissue in obese subjects, possibly due to the reduction of subcutaneous and perhaps also visceral APM1 mRNA levels, that accompany the obese state. Obese carriers of the T allele of APM1 G276T had higher adiponectin mRNA levels in visceral fat than carriers of the G/G genotype. This finding is in line with previous studies showing that the T allele of APM1 G276T has a positive influence on serum adiponectin levels. 10, 17, 18 Altered expression of genes due to cis-acting inherited allelic variations has been reported for a large number of genes. 32 It was recently shown that the first intron of the adiponectin gene is required for full transcriptional activation. This is mediated by interaction between the CCAAT/enhancer binding protein alpha and an intronic enhancer. 33 It is possible that similar enhancer or silencer regions could be found also in intron 2, although this has not yet been shown. Subcutaneous and visceral adipose tissues differ at several levels. For example, the expression levels of various adipokines 34 as well as the expression of several receptors 35 and transcription factors 35, 36 differ between the two adipose depots. Visceral fat is also more metabolically active than subcutaneous fat and adipokines produced by visceral adipose tissue have direct access to the liver. With these differences in mind it is possible that a variant in a gene could have effects in one but not in the other type of adipose tissue. Interestingly, despite a higher percent body fat, carriers of the APM1 G276T T allele had higher levels of 37 Although this is an appealing hypothesis we feel that it is too soon to make this conclusion, not least in view of the limited number of participants in this study, which was not designed to answer this question primarily. In light of our present data and previously published data on the T45G polymorphism, 17, 24 we were also interested in combinatorial effects between these polymorphisms and adiponectin expression. However, the frequency of the T45G allele was too low (0.08 for the G allele) in this material to perform such analyses.
In a transgenic mouse model lacking adipose tissue, adiponectin treatment normalized insulin sensitivity 38 and mice lacking adiponectin show impaired clearance of free fatty acid and develop diet-induced insulin resistance. 39 It has been suggested that adiponectin enhances insulin sensitivity by increasing fatty acid oxidation in muscle which in turn will result in reduced intramyocellular triglyceride content and improved glucose uptake. 39 We found a negative correlation between subcutaneous APM1 mRNA expression and fasting plasma triglyceride levels which may be an indicator of insulin resistance, but we were unable to detect significant correlations between HOMA and serum adiponectin or subcutaneous or visceral mRNA levels. This could be due to the use of HOMA as a surrogate measure of insulin sensitivity. To our knowledge, it has not been validated for this purpose in morbidly obese subjects. Correlations between HOMA and serum adiponectin and subcutaneous mRNA levels have been reported previously. 30, 40, 41 Motoshima et al. 22 showed that adiponectin secretion was higher from cultured human omental than from subcutaneous adipocytes. In the same study, they also showed that omental adiponectin secretion was increased after insulin treatment while subcutaneous secretion was unaffected. To that end, we found here that visceral APM1 expression correlated with serum adiponectin. In accordance with some, 42, 43 but not all 29, 41, 44 previous studies, we were not able to show a correlation between serum adiponectin levels and adiponectin mRNA levels in subcutaneous adipose tissue. The reason for this is not apparent but could reflect a greater role of visceral adipose tissue for adiponectin secretion. Although only visceral APM1 mRNA expression correlated with serum adiponectin levels, we did find negative correlations between subcutaneous APM1 mRNA expression and BMI and waist circumference. Subcutaneous APM1 mRNA expression has been found to be unaffected by diet in humans, 45 which is in line with experiments in rats showing increased levels of APM1 mRNA expression with weight reduction in visceral but not in subcutaneous adipose tissue. 46 It is tempting to speculate that the two adipose depots play different roles in adiponectin production and/or secretion and the maintenance of insulin sensitivity. There is convincing evidence that both adiponectin secretion and adiponectin mRNA expression are regulated by PPARg ligands 26 and PPARg/RXR heterodimers transactivate the human adiponectin promoter in vitro where it binds to PPARg-responsive element. 47 The Ala-allele of the PPARG Pro12Ala polymorphism has been associated with a reduced risk for type 2 diabetes in several populations. 48 The Pro12Ala polymorphism has also been suggested to affect the adiponectin plasma levels, Ala-carriers having lower APM1 expression in a Japanese population. 49 In line with results on adiponectin expression from a German population, 50 as well as on expression of other PPARg target genes in obese Finnish subjects, 51 we were not able to detect an effect of the PPARG Pro12Ala polymorphism on the expression of the adiponectin gene, neither in visceral nor in subcutaneous adipose tissue, suggesting that the effect of PPARg on adiponectin gene expression is not influenced by this polymorphism.
In conclusion, our results indicate that genetic variation in the adiponectin gene influences the expression of the gene in visceral adipose tissue and suggest a potential role for such variation in regulation of body fat accumulation in obese subjects.
